PREDI-LYNCH

Can liquid biopsy replace invasive surveillance for people with an inherited cancer predisposition?

Lynch syndrome carriers face sharply elevated risk of colorectal, endometrial and urothelial cancer. Current surveillance relies on repeated colonoscopy, which is burdensome and poorly adhered to.

Design: A six-year Horizon Europe consortium developing and validating non-invasive liquid biopsy tests for early detection in these three cancer types, using a randomised comparison against standard colonoscopy surve illance alongside a dedicated Lynch syndrome biobank. Coordinated by Oslo University Hospital with 28 partners across 16 European countries. Elypta contributes plasma and urine GAGome measurement.

Status: Project launched May 2025. The clinical study is sponsored by UNICANCER and not yet recruiting.

Funded by the European Union's Horizon Europe programme under grant agreement No 101213916. Registered at ClinicalTrials.gov (NCT07360834)

Project website: predi-lynch.eu